Novo Nordisk A/S (NVO) |
|
139.44 0.55 (0.4%)
|
03-17 16:00 |
|
Open: |
139.74 |
Pre. Close: |
138.89 |
|
High:
|
140.28 |
Low:
|
139.1 |
|
Volume:
|
1,582,032 |
Market Cap:
|
313,779(M) |
|
|
|
Technical analysis |
as of: 2023-03-20 8:48:14 AM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 165.71 One year: 170.45 |
| Support: |
Support1: 135.32 Support2: 112.58 |
| Resistance: |
Resistance1: 141.88 Resistance2: 145.94 |
| Pivot: |
142.13  |
| Moving Average: |
MA(5): 140.55 MA(20): 142.14 
MA(100): 130.85 MA(250): 117.49 |
| MACD: |
MACD(12,26): 0.2 Signal(9): 0.8 |
| Stochastic oscillator: |
%K(14,3): 30.7 %D(3): 30.2 |
| RSI: |
RSI(14): 45.7 |
| 52-week: |
High: 145.94 Low: 95.01 |
| Average Vol(K): |
3-Month: 1,443 (K) 10-Days: 1,792 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NVO ] has closed above bottom band by 11.9%. Bollinger Bands are 31.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
140.48 - 141.27 |
141.27 - 141.99 |
|
Low:
|
136.98 - 138.03 |
138.03 - 138.99 |
|
Close:
|
137.94 - 139.44 |
139.44 - 140.82 |
|
Company Description |
|
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. |
Headline News |
Mon, 20 Mar 2023
Novo Nordisk A/S (NVO) Up 2.27% in Premarket Trading - InvestorsObserver
Mon, 20 Mar 2023
Novo Nordisk A/S - share repurchase programme - GlobeNewswire
Sun, 19 Mar 2023
D. Scott Neal Inc. Makes New Investment in Novo Nordisk A/S ... - MarketBeat
Thu, 16 Mar 2023
Novo Nordisk Suspended From UK Trade Association For Practice Breaches - Yahoo Finance
Wed, 15 Mar 2023
Novo Nordisk A/S (NYSE:NVO) Shares Sold by Ascent Group LLC - MarketBeat
Tue, 14 Mar 2023
Novo Nordisk to slash US prices of insulin pens and vials by up to ... - Proactive Investors USA
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
2,250 (M) |
| Shares Float |
1,610 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
8.5 (%) |
|
Shares Short
|
1,090 (K) |
|
Shares Short P.Month
|
1,710 (K) |
Stock Financials |
|
EPS
|
3.44 |
|
EPS Est Next Qtl
|
0.52 |
|
EPS Est This Year
|
2.42 |
|
EPS Est Next Year
|
2.58 |
|
Book Value (p.s.)
|
37.09 |
|
Profit Margin (%)
|
31.3 |
|
Operating Margin (%)
|
42.7 |
|
Return on Assets (ttm)
|
21.6 |
|
Return on Equity (ttm)
|
72 |
|
Qtrly Rev. Growth
|
25.5 |
|
Gross Profit (p.s.)
|
66 |
|
Sales Per Share
|
78.64 |
|
EBITDA (p.s.)
|
35.96 |
|
Qtrly Earnings Growth
|
26.3 |
|
Operating Cash Flow
|
78,890 (M) |
|
Levered Free Cash Flow
|
57,500 (M) |
Stock Valuations |
|
PE Ratio
|
40.53 |
|
PEG Ratio
|
75.3 |
|
Price to Book value
|
3.75 |
|
Price to Sales
|
1.77 |
|
Price to Cash Flow
|
3.97 |
Stock Dividends |
|
Dividend
|
0.57 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0.4% |
|
Dividend Pay Date
|
2021-08-24 |
|
Ex-Dividend Date
|
2021-08-15 |
|
Your Ad Here
|
|
